Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MOVe-AHEAD trial

- PMLiVE

Dovetail wins Communiqué Agility and Flexibility award at Communiqué 2021

This inaugural award was given to Dovetail amid fierce competition from four other agencies

Transitioning to the “New Normal”: What This Means for Oncology Care

Dr. Burt Zweigenhaft, Co-founder of the Association for Value-Based Cancer Care, shares his thoughts on the importance of patient-centricity in cancer care, current barriers to value-based care in the US...

Impetus Digital

- PMLiVE

Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention

The MOVe-AHEAD trial will test whether the drug prevents infection in those living in the same household as someone with confirmed COVID-19

- PMLiVE

FDA’s director and deputy director of its Office of Vaccines Research & Review resign

The departure of director Marion Gruber and deputy director Philip Krause is unexpected

- PMLiVE

GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates

News:

Therapy Watch COVID-19 tracker

Research Partnership

- PMLiVE

US demand for COVID-19 antibody treatments rising fast

With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments

- PMLiVE

Merck’s Keytruda gains two more approvals in Japan

New approvals in breast and colorectal cancer take the number of indication for the immunotherapy mega-blockbuster to 15 in Japan

- PMLiVE

Pfizer/BioNTech file for FDA approval for COVID-19 booster jab

New data shows third dose boosts antibodies by more than three times

- PMLiVE

Protection against COVID-19 reduces over time in fully vaccinated, according to new real-world study

The Zoe COVID-19 Study shows protection could fall by up to 14%

- PMLiVE

FDA’s approval of Pfizer/BioNTech’s COVID-19 vaccine “is a milestone” says acting FDA commissioner Janet Woodcock

After more than a billion doses have been given worldwide, Comirnaty is now officially approved for people aged 16 and over in the US

- PMLiVE

AZ to seek approval for “long-acting” COVID-19 antibodies

AZD7442 significantly reduced the risk of developing symptomatic COVID-19 in phase 3 trial and is a one-dose treatment that can be given via an intramuscular injection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links